Citius Pharmaceuticals (FRA:47N0) Total Liabilities : €49.45 Mil (As of Dec. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Citius Pharmaceuticals Total Liabilities?

Citius Pharmaceuticals's Total Liabilities for the quarter that ended in Dec. 2024 was €49.45 Mil.

Citius Pharmaceuticals's quarterly Total Liabilities increased from Jun. 2024 (€10.04 Mil) to Sep. 2024 (€38.34 Mil) and increased from Sep. 2024 (€38.34 Mil) to Dec. 2024 (€49.45 Mil).

Citius Pharmaceuticals's annual Total Liabilities increased from Sep. 2022 (€10.68 Mil) to Sep. 2023 (€11.41 Mil) and increased from Sep. 2023 (€11.41 Mil) to Sep. 2024 (€38.34 Mil).

Citius Pharmaceuticals Total Liabilities Historical Data

The historical data trend for Citius Pharmaceuticals's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Citius Pharmaceuticals Total Liabilities Chart

Citius Pharmaceuticals Annual Data

Trend

Sep15

Sep16

Sep17

Sep18

Sep19

Sep20

Sep21

Sep22

Sep23

Sep24

Total Liabilities

Get a 7-Day Free Trial

8.58

8.20

10.68

11.41

38.34

Citius Pharmaceuticals Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Total Liabilities	Get a 7-Day Free Trial															11.06	9.88	10.04	38.34	49.45

Citius Pharmaceuticals Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Citius Pharmaceuticals's Total Liabilities for the fiscal year that ended in Sep. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	32.269	+	(0.019	+	0.0010000000000021
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	6.049	+	0	+	0)
	=	38.34

Total Liabilities	=	Total Assets (A: Sep. 2024 )	-	Total Equity (A: Sep. 2024 )
	=	105.103	-	66.766
	=	38.34

Citius Pharmaceuticals's Total Liabilities for the quarter that ended in Dec. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	42.79	+	(0	+	1.7763568394003E-15
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	6.664	+	0	+	0)
	=	49.45

Total Liabilities	=	Total Assets (Q: Dec. 2024 )	-	Total Equity (Q: Dec. 2024 )
	=	115.271	-	65.818
	=	49.45

Citius Pharmaceuticals Total Liabilities Related Terms

Thank you for viewing the detailed overview of Citius Pharmaceuticals's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Citius Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Citius Pharmaceuticals Inc (FRA:47N0) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

CTXR:USA

Address

11 Commerce Drive, First Floor, Cranford, NJ, USA, 07016

Website

https://www.citiuspharma.com

Citius Pharmaceuticals Inc is a biopharmaceutical company with a focus on anti-infectives in adjunct cancer care, prescription products, and stem cell therapy. The company is currently advancing four proprietary product candidates namely, LYMPHIR for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma. Mino-Lok, which is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections, Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries, Halo-Lido, a topical formulation that is intended to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids, and others.

Citius Pharmaceuticals Headlines

No Headlines